FIGURE LEGENDS
Figure 1. Side by side comparison of coronal CT imaging on diagnosis notable for significant ascites and large mass (A) , relapse with recurrent ascites (B) , and after 5 years on crizotinib therapy without malignant ascites and persistent necrotic mass (C).
Figure 2. Immunohistochemistry (IHC) for ALK demonstrated high expression throughout tumor samples. No pathologic mutations or gene rearrangements in ALK were identified on sequencing, but gross oncogenic over-expression of ALK was noted by IHC indicating ALK as a potential therapeutic target.